Alto Neuroscience’s (ANRO) Buy Rating Reiterated at Chardan Capital

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 price objective on the stock. Chardan Capital’s price objective would indicate a potential upside of 28.31% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. BTIG Research lifted their price target on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Wedbush lifted their price target on Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 17th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.33.

Alto Neuroscience Stock Up 4.0%

NYSE ANRO opened at $23.38 on Thursday. The business’s fifty day simple moving average is $19.09 and its 200-day simple moving average is $14.63. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The firm has a market cap of $746.90 million, a PE ratio of -10.72 and a beta of 2.52. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $25.17.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. As a group, equities analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds have recently made changes to their positions in ANRO. Commodore Capital LP acquired a new position in shares of Alto Neuroscience during the 4th quarter valued at $32,453,000. Perceptive Advisors LLC lifted its position in shares of Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP grew its stake in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Vivo Capital LLC acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $18,433,000. Finally, Ikarian Capital LLC grew its position in Alto Neuroscience by 368.2% in the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after buying an additional 405,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.